| home | about us | events | information | contact us | links |

EFNA funding arises from a small number of sources, including the pharmaceutical and medical device industries, the European Commission and others. Some of the grants are specific for particular EFNA projects and, where possible, we try to involve a consortium of donors for each project.
No donor, including the European Commission, has had any undue influence of any kind over EFNA’s activities, nor are there any conflicts of interest.
It is important to remember that EFNA is an extremely broadly-based organisation, which attempts to improve the quality of life for people in Europe living with neurological illness. Our projects are equally broad and tend to deal with issues generic to all or several neurological conditions and education rather than with specific drugs or other treatments. EFNA’s relationships within the pharmaceutical and medical device industry are usually at the level of government affairs and policy and our relationships with all sponsors/funders are regulated carefully by our “Code of Practice”.
Grants are listed by donor, with the percentage of total EFNA funding shown. These should be considered alongside funding in other years, as the figures below merely show the ‘snapshot’ of funds received as at 31 December in the year concerned.
The total amount of EFNA funding for each year may be found in the audited accounts, on this website but these accounts do not include, of course, any ‘donations in kind’ such as staff secondment. In the tables of percentages “EFNS” is the acronym for European Federation of Neurological Societies.
| 2006 | |
|---|---|
| Source | % of Total funding |
| Novartis (Restricted) | 2.62 |
| Movers and Shakers (UK Charity) | 15.40 |
| GSK (Restricted) | 1.93 |
| GE Healthcare (Restricted) | 15.03 |
| GSK (Unrestricted) | 14.48 |
| Alexion Pharma | 20.21 |
| GSK (Restricted) | 15.56 |
| European Parkinson's Disease | 0.39 |
| Eli Lilly (Resticted) | 2.05 |
| EFNS (Staff secondment) | 12.07 |
| Other | 0.26 |
| 2005 | |
|---|---|
| Source | % of Total funding |
| Britannia Pharma | 1.36 |
| Valeant | 1.37 |
| GSK | 2.72 |
| European Commission | 83.49 |
| Schering | 3.80 |
| Merck Sharpe & Dohme | 2.76 |
| Serono | 0.38 |
| EFNS (Staff secondment) | 3.92 |
| Other | 0.21 |
| 2004 | |
|---|---|
| Unrestricted grants | % of total funding |
| GlaxoSmithKline | 9.9 |
| Novartis | 29.6 |
| Merck Sharp & Dohme | 9.9 |
| Restricted Grant (EFNA Project) | |
| Novartis | 24.3 |
| Seconded Staff | |
| European Federation of Neurological Societies | 22.4 |
| Other small items of income | |
| Including bank interest | 3.9 |